Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Tocagen Inc.    TOCA

TOCAGEN INC.

(TOCA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
02/21/2020 02/24/2020 02/25/2020 02/26/2020 02/27/2020 Date
1.9(c) 2.09(c) 1.77(c) 1.7(c) 1.61 Last
51 775 311 21 995 610 5 048 516 2 879 092 1 498 148 Volume
+111.11% +10.00% -15.31% -3.95% -5.29% Change
More quotes
Financials (USD)
Sales 2019 0,01 M
EBIT 2019 -65,7 M
Net income 2019 -68,0 M
Debt 2019 -
Yield 2019 -
Sales 2020 1,51 M
EBIT 2020 -70,8 M
Net income 2020 -71,8 M
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -0,60x
P/E ratio 2020 -0,85x
Capi. / Sales2019 3 010x
Capi. / Sales2020 26,9x
Capitalization 40,6 M
More Financials
Company
Tocagen Inc. (Tocagen) is a clinical-stage, cancer-selective gene therapy company. The Company is focused on developing product candidates designed to activate a patient’s immune system against their own cancer. Its cancer-selective gene therapy platform is built on retroviral replicating vectors... 
More about the company
Surperformance© ratings of Tocagen Inc.
Trading Rating : Investor Rating :
More Ratings
Latest news on TOCAGEN INC.
04:11pTOCAGEN : Reports Fourth Quarter and Full Year 2019 Financial Results
PR
02/21TOCAGEN INC : Change in Directors or Principal Officers (form 8-K)
AQ
02/20TOCAGEN INC : Entry into a Material Definitive Agreement, Regulation FD Disclosu..
AQ
02/20TOCAGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
02/19TOCAGEN : and Forte Biosciences Announce Merger
PR
2019TOCAGEN INC : Entry into a Material Definitive Agreement (form 8-K)
AQ
2019TOCAGEN INC. : - Toca 5 Phase 3 Trial Results Presented at the Society for Neuro..
AQ
2019TOCAGEN INC : Regulation FD Disclosure, Other Events, Financial Statements and E..
AQ
2019TOCAGEN : Toca 5 Phase 3 Trial Results Presented at the Society for Neuro-Oncolo..
PR
2019TOCAGEN : Management's Discussion and Analysis of Financial Condition and Result..
AQ
2019TOCAGEN : Reports Third Quarter 2019 Financial Results and Business Updates
PR
2019TOCAGEN INC : Results of Operations and Financial Condition, Financial Statement..
AQ
2019TOCAGEN : Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer..
AQ
2019TOCAGEN : Highlights Toca 6 Phase 1b Data at Society for Immunotherapy of Cancer..
PR
2019TOCAGEN : to Report Third Quarter 2019 Financial Results and Business Updates on..
PR
More news
News in other languages on TOCAGEN INC.

- No features available -

More news
Chart TOCAGEN INC.
Duration : Period :
Tocagen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends TOCAGEN INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 5
Average target price 1,00  $
Last Close Price 1,70  $
Spread / Highest target -41,2%
Spread / Average Target -41,2%
Spread / Lowest Target -41,2%
EPS Revisions
Managers
NameTitle
Martin J. Duvall Chief Executive Officer & Director
Faheem Hasnain Chairman
Mark G. Foletta Chief Financial Officer & Executive Vice President
Sophie Visonneau Vice President-Clinical Operations
Fairooz Kabbinavar Senior Vice President-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
TOCAGEN INC.218.83%41
GILEAD SCIENCES7.88%94 394
VERTEX PHARMACEUTICALS5.98%60 161
REGENERON PHARMACEUTICALS17.81%49 848
WUXI APPTEC CO., LTD.20.01%25 883
GENMAB A/S11.00%15 615